Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Sarcoma × Rosiglitazone × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Polycystic Ovary Syndrome 2 Pituitary Neoplasms 2 Urinary Bladder Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Sezary Syndrome 1 Sarcoma 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Obesity 1 Mycosis Fungoides 1 Melanoma 1 Lymphoma, T-Cell, Cutaneous 1 Liposarcoma 1 Diabetes Mellitus, Type 2 1 Central Nervous System Neoplasms 1 Carcinoma, Hepatocellular 1 Breast Neoplasms 1 Adenocarcinoma Of Esophagus 1

Interventions

Doxorubicin 60 Radiotherapy 45 Ifosfamide 42 Gemcitabine 38 Cyclophosphamide 30 pazopanib 27 Docetaxel 25 pembrolizumab 23 Nivolumab 22 Filgrastim 22 Trabectedin 19 Etoposide 19 Surgical Procedures, Operative 18 Cisplatin 18 Blood Specimen Collection 16 Radiation 13 Carboplatin 13 Magnetic Resonance Spectroscopy 12 Ipilimumab 12 liposomal doxorubicin 11 Vincristine 11 Bevacizumab 11 apatinib 10 anlotinib 10 Temozolomide 10 Radiosurgery 10 Peripheral Blood Stem Cell Transplantation 10 Melphalan 10 Drug Therapy 10 Sorafenib 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00004180 2023-06-26

Rosiglitazone in Treating Patients With Liposarcoma

Dana-Farber Cancer Institute

Phase 2 Completed

Liposarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡